Cargando…
British Cancer Research Meeting, 30 June-3 July 2002, Glasgow
The 2002 British Cancer Research Meeting was held from 30th June to 3rd July in Glasgow, UK. The meeting was structured to include educational workshops, plenary lectures, symposia, and poster sessions, which brought together scientists and clinicians. Presentations ranged from the impact that modif...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC138745/ https://www.ncbi.nlm.nih.gov/pubmed/12223125 |
_version_ | 1782120488056651776 |
---|---|
author | Parkes, Alicia T Speirs, Valerie |
author_facet | Parkes, Alicia T Speirs, Valerie |
author_sort | Parkes, Alicia T |
collection | PubMed |
description | The 2002 British Cancer Research Meeting was held from 30th June to 3rd July in Glasgow, UK. The meeting was structured to include educational workshops, plenary lectures, symposia, and poster sessions, which brought together scientists and clinicians. Presentations ranged from the impact that modifications to basic chromatin structure can have on diagnosis and targeted gene therapy, to the outcome of novel therapeutics through clinical trials. The emphasis was clear: patient survival is the main priority and treatment of organ-specific cancer must inevitably be replaced by individualised tumour-specific therapy. |
format | Text |
id | pubmed-138745 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2002 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-1387452003-02-27 British Cancer Research Meeting, 30 June-3 July 2002, Glasgow Parkes, Alicia T Speirs, Valerie Breast Cancer Res Meeting Report The 2002 British Cancer Research Meeting was held from 30th June to 3rd July in Glasgow, UK. The meeting was structured to include educational workshops, plenary lectures, symposia, and poster sessions, which brought together scientists and clinicians. Presentations ranged from the impact that modifications to basic chromatin structure can have on diagnosis and targeted gene therapy, to the outcome of novel therapeutics through clinical trials. The emphasis was clear: patient survival is the main priority and treatment of organ-specific cancer must inevitably be replaced by individualised tumour-specific therapy. BioMed Central 2002 2002-07-29 /pmc/articles/PMC138745/ /pubmed/12223125 Text en Copyright © 2002 BioMed Central Ltd |
spellingShingle | Meeting Report Parkes, Alicia T Speirs, Valerie British Cancer Research Meeting, 30 June-3 July 2002, Glasgow |
title | British Cancer Research Meeting, 30 June-3 July 2002, Glasgow |
title_full | British Cancer Research Meeting, 30 June-3 July 2002, Glasgow |
title_fullStr | British Cancer Research Meeting, 30 June-3 July 2002, Glasgow |
title_full_unstemmed | British Cancer Research Meeting, 30 June-3 July 2002, Glasgow |
title_short | British Cancer Research Meeting, 30 June-3 July 2002, Glasgow |
title_sort | british cancer research meeting, 30 june-3 july 2002, glasgow |
topic | Meeting Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC138745/ https://www.ncbi.nlm.nih.gov/pubmed/12223125 |
work_keys_str_mv | AT parkesaliciat britishcancerresearchmeeting30june3july2002glasgow AT speirsvalerie britishcancerresearchmeeting30june3july2002glasgow |